Recurrent Hepatocellular Carcinoma Clinical Trials

26 clinical trials for Recurrent Hepatocellular Carcinoma across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors — RECRUITING · PHASE1
• Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC — RECRUITING · PHASE2
• The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma — RECRUITING · NA
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors — ACTIVE_NOT_RECRUITING · PHASE2
• Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer — COMPLETED · PHASE3
• Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma — SUSPENDED · PHASE1
• Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV — ACTIVE_NOT_RECRUITING · PHASE1
• Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant — TERMINATED · PHASE2
• IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer — TERMINATED · PHASE2
• Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors — COMPLETED · PHASE1
• Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization — TERMINATED · PHASE3
• The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC — OTHER
• Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC — OTHER · PHASE2
• Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma — WITHDRAWN · PHASE2
• A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation — WITHDRAWN · PHASE1
• TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation — OTHER · PHASE1
• A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation — OTHER · PHASE1
• Stereotactic Body Radiotherapy and Microwave Ablation for Recurrent Small Hepatocellular Carcinoma — OTHER · NA
• Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence — COMPLETED · PHASE2
• Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors — COMPLETED · PHASE1
• Comparison of Treatment of Recurrent HCC With Repeat Hepatectomy,and TACE With AFP Conversion — COMPLETED · NA
• Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma — COMPLETED
• Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC) — WITHDRAWN · PHASE3

Refine this search